Immatics N.V. IMTX
Set alert
At close · Oct 30
After hours · Oct 30, 4:33 PM ET
- YTD
- -31.43%
- 1 year
- -30.90%
- Open
- 7.26
- Prev close
- 7.31
- Mkt cap
- 1.10B
- Vol
- 1.72M
- Avg vol
- 786.58K
- EPS
- -1.87
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.81
- High
- 7.40
- Forward P/E
- -3.57
- Beta
- 1.36
- Short ratio
- 4.03
- Inst. own
- 66.81%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 17, 2026
- 50-d avg
- 8.28
- 200-d avg
- 9.60
- 1y target
- 16.97
6M chart
Events in this range
- May 12, 2026Earnings: -0.5; estimate -0.42; surprise -19.05%
- May 19, 2026Rating: Chardan Capital · Buy → Buy
- Aug 18, 2026Earnings: -0.53; estimate -0.47984; surprise -10.45%
- Oct 14, 2026Rating: Stifel · — → Buy
Signals (23)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 12, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 8, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 1, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 30, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| SMA: Bullish | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 27, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 19, 2026 | 2 months ago |
| SMA: Bearish | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Aug 6, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 22, 2026 | 4 months ago |
| RSI: Oversold | Jun 10, 2026 | 4 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 1, 2026 | 5 months ago |
| MACD: Buy Signal | May 28, 2026 | 5 months ago |
Key statistics
- Market cap
- 1.10B
- Enterprise value
- 620.46M
- Trailing P/E
- 0.00
- Forward P/E
- -3.57
- PEG ratio
- 0.00
- Price / sales
- 26.28
- Price / book
- 2.19
- EPS (TTM)
- -1.87
- Beta
- 1.36
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 41.70M
- Revenue growth
- 93.00%
- Free cash flow
- -126.54M
- Total cash
- 393.35M
- Total debt
- 14.61M
- Return on equity
- -47.80%
- Shares outstanding
- 152.23M
- Short % of float
- 3.41%
- 50-day average
- 8.28
- 200-day average
- 9.60
Analyst view
Consensus: strong buy
- Target (low)
- 11.80
- Target (mean)
- 16.97
- Target (high)
- 25.00
- Strong buy0
- Buy9
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 17, 2026
Expected Nov 17, 2026. Consensus EPS estimate -0.4985.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 17, 2026 | Sep 30, 2026 | -0.49 | — | — | — |
| Aug 18, 2026 | Jun 30, 2026 | -0.47984 | -0.53 | -0.05 | -10.45% |
| May 12, 2026 | Mar 31, 2026 | -0.42 | -0.50 | -0.08 | -19.05% |
| Mar 5, 2026 | Dec 31, 2025 | -0.48 | -0.34 | +0.14 | +29.17% |
| Nov 17, 2025 | Sep 30, 2025 | -0.43933 | -0.49 | -0.05 | -11.53% |
| Aug 13, 2025 | Jun 30, 2025 | -0.38 | -0.66 | -0.28 | -73.68% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 14, 2026 | Stifel | init | — | Buy |
| May 19, 2026 | Chardan Capital | main | Buy | Buy |
| Apr 28, 2026 | TD Cowen | init | — | Buy |
| Nov 24, 2025 | Chardan Capital | main | Buy | Buy |
| Nov 19, 2025 | Mizuho | main | Outperform | Outperform |
| Nov 18, 2025 | Guggenheim | main | Buy | Buy |
About Immatics N.V.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Germany
- Website
- immatics.com
News
- Reported Saturday, Immatics Reports IMA203CD8 Cell Therapy 51% ORR, 41% cORR Across Multiple Solid Tumors With Manageable Safety; IMA402 Bispecific Shows 32% cORR In PRAME-High Melanoma, Favorable Safety Profile
- Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
- This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
- Stifel Initiates Coverage On Immatics with Buy Rating, Announces Price Target of $15
- Immatics (NASDAQ:IMTX) vs. Kyntra Bio (NASDAQ:KYNB) Financial Contrast
- Immatics (NASDAQ:IMTX) Reaches New 1-Year Low – Here’s Why
- Immatics (NASDAQ:IMTX) Sees Strong Trading Volume – Still a Buy?
- Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma
- Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday
- Immatics Announces $150M Underwritten Offering Of Ordinary Shares And Pre-Funded Warrants
Your note
Sign in to keep a note on IMTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS, L.L.C. | Director | Purchase | Aug 25, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 16.36% | 22,365,046 | 161.03M | Jun 29, 2026 |
| RTW Investments LP | 9.47% | 12,946,176 | 93.21M | Jun 29, 2026 |
| Montanova Capital LLC | 8.19% | 11,190,129 | 80.57M | Jun 29, 2026 |
| Perceptive Advisors Llc | 7.60% | 10,383,456 | 74.76M | Jun 29, 2026 |
| Baker Bros. Advisors, LP | 6.96% | 9,508,565 | 68.46M | Jun 29, 2026 |
| Jefferies Financial Group Inc. | 4.76% | 6,506,802 | 46.85M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 3.84% | 5,244,466 | 37.76M | Jun 29, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 3.78% | 5,165,834 | 37.19M | Jun 29, 2026 |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Value Equity Trust | 2.48% | 3,395,058 | 24.44M | Jun 29, 2026 |
| T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 2.09% | 2,854,678 | 20.55M | Jun 29, 2026 |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Core Equity Trust | 1.78% | 2,433,632 | 17.52M | Jun 29, 2026 |
| abrdn World Healthcare Fund | 0.34% | 466,940 | 3.36M | Jun 29, 2026 |